Ovaj virus nije ništa drugo do jedan od sojeva SARS virusa iz 2003. godine. Taj virus, nakon što je isčežao, ostao je samo kao primjerak za dalje izučavanje, upravo u ovoj laboratoriji. Čak i vakcina koja je razvijana za SARS (AstraZeneca), uz minorne izmjene, djelotvorna je i protiv SARS-CoV2 virusa (izvorni virus nosi oznaku SARS-CoV). Ovo nije ništa drugo do "curenje" virusa iz laboratorije, koji je u toku te transmisije malo i mutirao i tako nastao virus/soj SARS-CoV2.
Originalni SARS (SARS-CoV):
Današnji Koronavirus (SARS-CoV2):
Isti simptopmi, isti način vezivanja za ćelije, isti način prenošenja, ista klinička slika, ista vakcina djelotvrona (ovo je pretpostavka, nije još uvijek potvrđeno, ali uzmimo da djeluje).
The SARS-CoV-2 virus is genetically closely related to severe acute respiratory syndrome coronavirus (SARS-CoV), the first pandemic threat of a novel and deadly coronavirus that emerged in late 2002 and caused an outbreak of severe acute respiratory syndrome (SARS). SARS-CoV was highly lethal but faded out after intense public health mitigation measures.2 By contrast, the novel SARS-CoV-2 that emerged in December, 2019, rapidly caused a global pandemic. The SARS 2003 outbreak ceased in June, 2003, with a global total of 8098 reported cases and 774 deaths, and a case fatality rate of 9·7%, with most cases being acquired nosocomially.2 In comparison, the Middle East respiratory syndrome coronavirus (MERS-CoV)—another deadly coronavirus, but which is currently not presenting a pandemic threat—emerged in 2012, and has caused 2494 reported cases and 858 deaths in 27 countries and has a very high case fatality rate of 34%.3 Because MERS-CoV is widespread in dromedary camels, zoonotic cases continue to occur, unlike SARS-CoV, which emerged from wildlife and was eliminated from the intermediate host reservoir.
The new coronavirus SARS-CoV-2 is less deadly but far more transmissible than MERS-CoV or SARS-CoV. The virus emerged in December, 2019, and as of June 29, 2020, 6 months into the first pandemic wave, the global count is rapidly approaching 10 million known cases and has passed 500 000 deaths.4 Because of its broad clinical spectrum and high transmissibility, eradicating SARS-CoV-2, as was done with SARS-CoV in 2003, does not seem a realistic goal in the short term.
In this Personal View we summarise key epidemiological characteristics of SARS-CoV-2 in comparison with other epidemic coronaviruses and pandemic influenza. We explore what makes SARS-CoV-2 different from pandemic influenza virus and the other epidemic severe coronaviruses such as SARS-CoV and MERS-CoV. We study the various characteristics of each virus, including the transmission and severity characteristics, case fatality rates (mortality in individuals with the disease), and the population-level mortality of the SARS-CoV-2 pandemic
https://www.thelancet.com/journals/lani ... 9/fulltext
SARS-CoV je smrtonosniji u odnosu na SARS-CoV2. To je još jedan od pokazatelja da je SARS-CoV2 soj koji je nastao od originalnog SARS-CoV virusa. Svaki virus mutira i nastoji sebi produžiti vijek. Mutirao je na način da je smanjio smrtnost domaćina, a poboljšao prijenos jer kad domaćin umre, umire i virus sa njim. Vidimo da svi ovi sojevi koji se pojavljuju mutiraju na sličan način.
I na kraju, sve su veći izgledi da je neko u laboratoriji debelo zajebao stvar i "pustio" SARS napolje. Da li zbog nestučnosti, ili pak namjerno, to je za posebnog istraživanja.